Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$10.71 - $17.11 $119,716 - $191,255
-11,178 Reduced 47.37%
12,419 $156,000
Q2 2024

Jul 29, 2024

SELL
$3.89 - $20.97 $12,020 - $64,797
-3,090 Reduced 11.58%
23,597 $298,000
Q1 2024

Apr 29, 2024

BUY
$3.76 - $6.02 $7,392 - $11,835
1,966 Added 7.95%
26,687 $127,000
Q4 2023

Feb 07, 2024

BUY
$4.8 - $7.67 $5,851 - $9,349
1,219 Added 5.19%
24,721 $118,000
Q3 2023

Nov 02, 2023

BUY
$6.81 - $9.74 $483 - $691
71 Added 0.3%
23,502 $170,000
Q2 2023

Aug 07, 2023

BUY
$6.67 - $9.52 $22,824 - $32,577
3,422 Added 17.1%
23,431 $174,000
Q1 2023

May 09, 2023

SELL
$5.76 - $12.48 $10,690 - $23,162
-1,856 Reduced 8.49%
20,009 $138,000
Q4 2022

Feb 09, 2023

BUY
$8.86 - $25.04 $34,926 - $98,707
3,942 Added 21.99%
21,865 $224,000
Q3 2022

Nov 09, 2022

SELL
$18.2 - $76.12 $25,407 - $106,263
-1,396 Reduced 7.23%
17,923 $326,000
Q2 2022

Aug 10, 2022

BUY
$36.28 - $75.29 $55,508 - $115,193
1,530 Added 8.6%
19,319 $994,000
Q1 2022

May 09, 2022

SELL
$69.73 - $142.9 $72,867 - $149,330
-1,045 Reduced 5.55%
17,789 $1.31 Million
Q4 2021

Feb 09, 2022

SELL
$134.56 - $217.97 $3.74 Million - $6.06 Million
-27,815 Reduced 59.63%
18,834 $2.69 Million
Q3 2021

Nov 09, 2021

BUY
$177.8 - $270.58 $3.92 Million - $5.96 Million
22,033 Added 89.51%
46,649 $9.67 Million
Q2 2021

Aug 10, 2021

BUY
$121.0 - $257.67 $332,145 - $707,304
2,745 Added 12.55%
24,616 $5.23 Million
Q1 2021

May 10, 2021

BUY
$112.98 - $319.93 $242,681 - $687,209
2,148 Added 10.89%
21,871 $3.97 Million
Q4 2020

Feb 08, 2021

BUY
$78.74 - $139.5 $356,455 - $631,516
4,527 Added 29.79%
19,723 $2.2 Million
Q3 2020

Nov 06, 2020

SELL
$79.44 - $178.51 $145,534 - $327,030
-1,832 Reduced 10.76%
15,196 $1.65 Million
Q2 2020

Aug 05, 2020

BUY
$13.86 - $83.61 $236,008 - $1.42 Million
17,028 New
17,028 $1.42 Million

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $662M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.